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Abstract: Folate is a generic term for a water-soluble B-complex vitamin which plays an
important role in protein synthesis and metabolism and other processes related to cell multiplication and tissue growth. Pregnant and lactating women are at increased risk of folic acid
deficiency because generally their dietary folate is insufficient to meet their physiological
requirements and the metabolic demands of the growing fetus. The evidence pertaining to the
reduction of the risk of neural tube defects (NTDs) due to folate is so compelling that supplementation with 400 µg of folic acid to all women trying to conceive until 12 weeks of pregnancy
has been recommended by every relevant authority. A recent Cochrane review has also found
protective effects of folate supplementation in occurrence and reoccurrence of NTDs. Despite
food fortification and targeted public health campaigns promoting folic acid supplementation,
4,300,000 new cases occur each year worldwide resulting in an estimated 41,000 deaths and
2.3 million disability-adjusted life years (DALYS). This article will review the burden and
risk factors of NTDS, and the role of folate in preventing NTDs. It will also describe different
modes of supplementing folate and the newer evidence of the effectiveness of adding folate in
oral contraceptives for raising serum and red blood cell folate levels.
Keywords: folate, folate-containing oral contraceptives, oral contraceptives, contraceptives

Neural tube defects (NTDs), which include anencephaly, spina bifida, and encephalocele,
are congenital malformations that arise during the structural development of the neural
tube, a process that is completed within 28 days after conception.
Anencephaly is invariably associated with death either as stillbirth, neonatal death
or occasionally postneonatal death. Encephalocele and spina bifida may be associated
with neonatal death, infant death or with impairment which is frequently severe in
the absence of surgery including lower limb paralysis, incontinence, convulsions and
frequent central nervous system (CNS) infections. Less severe defects include spina
bifida occulta which can also have long-term neurological sequelae, but rarely causes
neonatal death (Table 1).1
NTDs are an important cause of mortality and morbidity globally with a conservative estimated incidence of 4,300,000 new cases a year2 resulting in an estimated
41,000 deaths and 2.3 million disability-adjusted life years (DALYS).3 In addition, the
lifetime direct cost associated with spina bifida is US$279,210.4 They thus comprise
about one-tenth of the burden of all neonatal mortality5 and 10% of all congenital
conditions and constitute the third largest congenital burden after congenital heart
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Table 1 Categories of neural tube defects, their causes and prognosis
Anencephaly

Encephalocele

Spina bifida

Cause

Failure of closure of the anterior
(cranial) neural arch

Failure of closure of the posterior
(cranial) vertebral arch

Prognosis

Stillbirth or neonatal death

Failure of closure of the anterior
(cranial) neural arch at a later stage
of embryogenesis than anencephaly
Mortality from meningitis

disease and Down’s syndrome.3 Over 95% of all NTDs are
first occurrence; with a small proportion being repeat events
in women with a previously affected pregnancy.6 Risk factors
include genetic factors, environmental factors, particularly
folic acid deficiency at the time of conception, diabetes
and obesity and other predisposing maternal factors.7 The
prevalence of NTDs varies in different racial and ethnic
groups,8,9 particularly in consanguineous marriages leading
to genetic abnormalities,10 causing NTDs in current and
recurrence in subsequent pregnancies.7,11 Environmental
risk factors include maternal diabetes,12 use of valproic
acid,13 hyperthermia,14,15 obesity,16–18 occupational exposure
to agricultural19 and cleaning products.20,21 In most studies,
the countries where a folate-rich diet is not available to all,
NTDs are highest among the economically disadvantaged
population subgroups.22–25 Even in high-income countries,
lower maternal education status is associated with higher
risk of NTDs.23,26 Over the past decades many countries
have reported a reduction in prevalence of NTDs at birth
mainly because of second-trimester screening and termination of affected pregnancies27 and partly because of folic acid
supplementation.28
Certain gene polymorphisms are responsible for folate
metabolism and are associated with decreased folate absorption
thus increasing folate needs. One of the prominent variants
are the methylene-tetrahydrofolate reductase (MTHFR)
gene and Solute carrier family 19 (folate transporter),
member 1 (SLC19A1) gene.29 With reduced folate intake in
diet, MTHFR and SLC19A1 genetic variations are associated
with increased risk of NTDs and conotruncal defects in the
offspring.30–32 It was found to be associated with more than
80 genetic abnormalities (trisomy 13 and 18 and autosomal
recessive syndromes, such as Meckel–Gruber). On the other
hand, environmental factors, including nutrition, are thought to
contribute to about 5% to 10% of total birth defects.33
These conditions can be diagnosed antenatally. Elevated
concentration of alpha-feto-protein in maternal serum can
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Disability ranges from
Neurological: sensory and motor defects,
learning disability and epilepsy
Orthopedics: contractures, joint
dislocations, and talipes
Functional: bladder and bowel dysfunction

raise the suspicion of NTD; the diagnosis can further be established by ultrasound examination during the second trimester
of pregnancy. Unfortunately, these tests are not routinely
done in most developing countries as yet.34–36 However, the
combinations of maternal serum screening programs and
sonographic findings have enabled the prenatal diagnosis
of spina bifida in more than 90% of cases.37 Although the
prenatal diagnosis of spina bifida maximizes the reproductive
options for women, it is yet unclear which fetuses would
benefit from prenatal therapy, because the natural history
and the sonographic signs of progressive neurologic damage
have not been well characterized.

Role of folic acid in prevention
of neural tube defects
Folate is a generic term for a water soluble B-complex
vitamin, and it serves as co-factor in transfer of single carbon
during the methylation cycle responsible for the synthesis of
DNA, neurotransmitters, and gene expression.38,39 Folate also
plays an important role in protein synthesis and metabolism
and other processes related to cell multiplication and tissue
growth.40 The main consequence of folate deficiency in
adults is megaloblastic anemia, characterized by abnormally
large red cell precursors in the bone marrow and larger than
normal red cells in the peripheral blood. The methylation of
homocysteine to produce methionine (both essential amino
acids) uses 5-Methylene-tetrahydrofolate (5-MTHF) (folate
and folic acid are metabolized to 5-MTHF during its passage
across the intestinal mucosa) as the methyl donor in the
reaction. In folate deficiency, homocysteine accumulates in
the serum and is found to be associated with an increased
risk in cardiovascular disease,41 late pregnancy complications
such as pre-eclampsia,42–44 and NTDs around the time of
conception.40
Pregnant and lactating women are at increased risk of
folic acid deficiency because generally their dietary folate
is insufficient to meet the physiological requirements and
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the metabolic demands of the mother and the growing
fetus.45,46
In 1991, a multicenter, multinational randomized prevention trial by the British Medical Research Council (MRC)
Vitamin Study Group, presented the first beneficial impacts
of folic acid supplementation.46 The study was initiated in
1983 and was halted in 1991, when it was felt that the results
warranted the prescription of folic acid supplementation to
all study participants. The study enrolled 1817 women who
had a previous pregnancy with an infant or fetus with a neural
tube abnormality and were planning another pregnancy. In this
study, one group was given 4000 µg of folic acid, the second
group a multivitamin with 4000 µg of folic acid, the third
group was given no supplementation, while the final group
received a multivitamin without folic acid. The analysis of
the trial results showed that folic acid supplementation was
associated with a 71% reduction in NTDs. The study also
demonstrated that such results were achieved only when
supplementation began before conception and continued
through the first three months of the pregnancy.
In a span of a year, another major trial from Hungary
presented their results of folic acid supplementation on
women without a previous history of NTD pregnancy. The
results from this trial indicated that a multiple micronutrient
supplement containing 800 µg of folic acid prevented the
occurrence of NTDs.47
While maternal intake of folate and folic acid is specifically associated with a decreased risk for NTDs, the results
from those trials showed that it also provides protection
for other selected birth defects. Approximately half of the
birth defects are limited to a single organ and the other
half frequently present additional birth defects.48 Affected
infants also face difficulty with feeding and later with speech
development, hearing and tooth formation. Malnutrition
and infection can further lead to severe illness and, in some
cases, death.48
A recent Cochrane review of five trials involving
6105 women (1949 with a history of a pregnancy affected by
an NTD and 4156 with no history of NTDs), shows a protective
effect of daily folic acid supplementation in doses ranging from
360 µg to 4000 µg a day, with and without other vitamins and
minerals, before conception and up to 12 weeks of pregnancy,
for preventing the occurrence of NTDs by 72% (relative risk
[RR] 0.28; 95% confidence intervals [CI]: 0.15–0.52) and
reoccurrence by 68% (RR 0.32; 95% CI: 0.17–0.60).49
Another review published in International Journal of
Epidemiology in 2010 presented the meta-analysis of eight,
population based observational studies examining the impact
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of folic acid fortified food and reported reduced NTDs
incidence (RR 0.54; 95% CI: 0.46–0.63).50

Sources of folic acid and rationale
for the fortification of oral
contraceptives
Folate is naturally present in legumes, lentils, kidney beans,
green peas, corn, beets, leafy green vegetables (such as
spinach, broccoli, iceberg lettuce, asparagus, and turnip
greens) and some citrus fruits and juices (such as oranges,
strawberries, and tomato). Folic acid is the synthetic and most
stable form of folate and is often used in supplements and fortified foods. The bioavailability of folic acid is approximately
70% higher in fortified foods than that of folate naturally contained in foods, although there are wide variations depending
on the methodology used in the measurement.51
In 1992, after the emergence of evidence of reduced
occurrence of NTDs with folic acid supplementation, the
World Health Organization (WHO) recommended 400 µg
of folic acid to all women trying to conceive until 12 weeks
of pregnancy.52 Since then daily supplementation with folic
acid, in addition to iron, is routinely recommended for all
pregnant women to prevent anemia.53 Women are usually
supplemented with folic acid tablets, however, in many
countries governments have also introduced the concept of
folate-fortified food programs, in which folic acid is added
to flour, maize, or cereals to increase serum folate levels in
the population.
While fortification is felt to be the best way to ensure
that women of child-bearing age receive supplementation in
the months preceding pregnancy and in the critical window
when a woman might not know that she is pregnant, folic
acid supplementation does not ensure this. Women not on
folate supplementation who unintentionally become pregnant
may be late in starting folate supplementation, and thus
fail to reach the required levels to reduce the risk of NTDs,
even if they initiate oral supplementation the moment their
pregnancy is established.
As most women of reproductive age do not get
adequate amounts of folate in their diets and do not seek
preconceptional care, it is obvious that newer approaches are
needed to reach women at risk for pregnancy. Hence recently,
fortifying oral contraceptive with folate was tested and
recommended by the United Nations and the US Food and
Drug Administration (FDA) with the reason that women may
become pregnant during use or shortly after discontinuation,
possibly before seeking preconception counseling from their
healthcare provider. It is particularly important for women
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who want to use an oral contraceptive, to offer them daily
folate supplementation. The oral contraceptive as a vehicle to
supply folate is important because its users are sexually active
and it is the most popular method of birth control, especially
among young women, who are the age group with the greatest
number of pregnancies both intended and unintended. It not
only raises plasma and red blood cells (RBC) folate levels
but also provides required folate levels until women adopt
another effective contraceptive method or become pregnant
and initiate folic acid supplementation.

Safety, tolerability and efficacy
studies on folate containing oral
contraceptives
In 2010, the FDA approved Beyaz® and Safyral® (Bayer
Health Care Pharmaceuticals Inc, Wayne, NJ) oral contraceptives, which have both estrogen (20 µg ethinyl estradiol) and
progestin (3000 µg of drospirenone) and also contain a folate
(451 µg levomefolate calcium – also known as 5-MTHF and
L-methylfolate). Two clinical trials have examined the effects
of these folate-containing oral contraceptives on RBC folate
levels which became the basis of this drug aproval.54–57
The US Benefit study compared an oral contraceptive
containing drospirenone and ethinyl estradiol plus folate
with the nonfolate-fortified version of the oral contraceptive in a multicenter, double-blind, randomized activecontrolled trial on 379 healthy women aged 18–40 years
who had been exposed to folate-fortified food.57,58 Folate
levels were assessed in the plasma and RBC every 2 weeks
for the 24-week study period. The women using the folatefortified oral contraceptives demonstrated significant increase
(15.8 nmol/L) in serum folate levels. These levels were
consistently maintained throughout the study period. In the
nonfolate-fortified arm, plasma folate levels decreased by
2.2 ± 14.6 nmol/L. Significant differences were also seen in
the mean RBC folate levels. In the control group, RBC folate
levels increased by 34.3 nmol/L, while in the folate-fortified
oral contraceptive users, a mean increase from baseline of
419.9 ± 347 nmol/L (P , 0.001) was observed.
The European Long-term Folate Study, on the other hand,
compared the combination of folate in an oral contraceptive
given orally in a cyclic regimen for 24 weeks (6 cycles), with
the same oral contraceptive administered separately with
folic acid tablets in German women who had no exposure
to folate-fortified food.54,55 It was a double-blind, 24-week
trial followed by an open-label 20-week follow-up with a
nonfortified oral contraceptive to evaluate the elimination
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of folate from the body over time. At each point in time, the
folate-fortified oral contraceptive women had higher levels of
folate in both serum and RBC than women who took the folic
acid supplements in addition to oral contraceptives. During
the second phase of follow up, folate levels were found to be
diminished but remained over the baseline levels.
While the importance of folate-fortifying oral contraceptives was established by these two trials and the persistence
of the elevation in folate levels was quantified, for some clinicians, supplementing oral contraceptives with folate seems
counterintuitive. Notwithstanding, birth control pills represent
the most popular contraceptive choice, although they have a
relatively high failure rate. Thus, an oral contraceptive that
contains folate has appeal and full potential to supplement
women with folate at the time of conception.
Given the potential individual and public health benefits,
folate-containing oral contraceptives have some overlapping
adverse reactions across three indications: contraception, acne,
and folate supplementation. The most common treatmentemergent adverse reactions are headache/migraine, menstrual
irregularities (spotting, metrorrhagia, and menorrhagia), nausea/
vomiting, and breast pain/tenderness.59 At the same time, oral
contraceptives are contraindicated in women with a high risk of
arterial or venous thrombotic diseases, undiagnosed abnormal
uterine bleeding, breast cancer or other hormone-sensitive cancer,
liver tumors (benign or malignant) or liver disease, conditions
that predispose to hyperkalemia (ie, renal impairment, hepatic
dysfunction, and adrenal insufficiency), or who are pregnant.59

Conclusions and future directions
Neural tube closure occurs during the first month after conception, often before a woman is aware of her pregnancy
status. The potential to reduce the incidence of NTDs with
folate supplementation is well established based on a body
of evidence derived from randomized, controlled trials.
Every relevant authority recommends that all women of
childbearing potential consume at least 400 µg of folic acid
daily. There are many ways to obtain supplemental folic acid.
The folate-containing oral contraceptive is a novel way to
increase folic acid levels in women of childbearing age who
choose birth control pills for contraception. While the FDA
has approved this drug based on two clinical trials from developed countries, the drug still requires assessment in terms of
its efficacy and effectiveness in different age groups and in
regions with low contraceptive prevalence rates. This might
not be effective in the context of the developing world as
contraceptive usage rates are not comparable to the developed
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world. Coverage rates need to be improved for contraceptives
in these regions; also efforts need to be made to strategize
effective means of folic acid delivery in these regions.
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